



European Guidelines for Treatment of Bifurcation Coronary Lesions

Y. Louvard, ICPS, Massy, France


TCT Asia Pacific 2010



No conflict of interest to declare



Side branch diameter and length can both be used as surrogates for volume of muscle at risk




SB diameter as an index of MI

$$%Infarct_{artery} = M_{SB}/M_{MP} x100 =$$
 $(CSA_{SB}/CSA_{MP})^{4/3} x 100$
where SB-Side branch; MP-Most proximal artery (e.g., LAD, LCx or

- A quantitative relation between SB
 diameter/area and %Infarct (relative to main
 artery or entire heart) exists in swine hearts and
 needs to be established in patients
- Correlate with clinical biomarkers (biological, molecular, imaging, etc.)

RCA)

Microinfarction after minor SB occlusion



Side branch < 1,5 mm / CK 260 U/I


How to Define a Bifurcation Lesion?

A coronary artery narrowing occurring adjacent to, and/or involving, the origin of a significant side branch.

A significant SB is a branch that you don't want to lose in the global context of a particular patient




Bifurcation branching law (Murray)





Finet's law


$$D_1 = 0.67(D_2 + D_3)$$



Branching law and main vessel stenting










Postdilatation, or kissing balloon inflations, are required to optimise the proximal main vessel stent diameter

Fractal geometry and QCA





Reference diameter function is not linear






Medina Classification







Name the bifurcation

- Why ?: for Medina classification (which branch is the SB ?)
 - for stenting technique definition
 - for intention to treat analysis



MADS classification of bifurcation stenting techniques





B.

Myocardial Infarction

Study	Year	Events /	Total		MH ris	k ratio a	nd 95% CI				
		Provisional	Two stents						MH risk ratio	Lower limit	Upper limit
Pan et al.	2004	2 / 47	0 / 44		16.	4 9	-		4.69	0.23	95.00
Colombo et al.	2004	2 / 22	7 / 63				_		0.82	0.18	3.65
NORDIC	2006	0 / 207	1 / 206	<u> </u>					0.33	0.01	8.10
Ferenc et al.	2008	1 / 101	2 / 101		3 6	200			0.50	0.05	5.43
BBC ONE	2008	9 / 250	28 / 250			H -			0.32	0.15	0.67
CACTUS	2009	15 / 173	19 / 177			-44-	11		0.81	0.42	1.54
Overall		29 / 800	57 / 841			-			0.57	0.37	0.87
				0.01 Favor	0.1 s Provisio	1 onal	10 Favors Tw	100 o Stents			
					150.00		5.72, df=5, P= 2.51, P=0.01	±0.33 (≥±13	(778)	ed Effect	s Model

C. TLR

Study Yes		ar Events / Total		MH risk ratio and 95% CI	Statistic	Statistics for each study			
		Provisional	Two stents		MH risk ratio	Lower limit	Upper limit		
Pan et al.	2004	1 / 47	2/44		0.47	0.04	4.98		
Colombo et al.	2004	1 / 22	6 / 63		0.48	0.06	3,75		
NORDIC	2006	4 / 207	2 / 206	-	1.99	0.37	10.75		
Ferenc et al.	2008	11 / 101	9 / 101	-	1.22	0.53	2.82		
BBC ONE	2008	14 / 250	18 / 250	-	0.78	0.40	1.53		
CACTUS	2009	11 / 173	13 / 177		0.87	0.40	1.88		
Overall		42 / 800	50 / 841	•	0.91	0.61	1.35		

Fixed Effects Model

E.


Stent Thrombosis

Year	Events /	Total		MH ris	k ratio a	and 95% CI				
	Provisional	Two stents						MH risk ratio	Lower limit	Upper limit
2004	0 / 47	1 / 44	I	-				0.31	0.01	7.47
2004	0 / 22	3 / 63						0.40	0.02	7.40
2006	1 / 207	0 / 206		ļ 	-			2.99	0.12	72,87
2008	2 / 101	2 / 101		-	-•			1.00	0.14	6.96
2008	1 / 250	5 / 250		- 18				0.20	0.02	1.70
2009	2 / 173	3 / 177		-	-	<u> </u>		0.68	0.12	4.03
0000000	6 / 800	14 / 841	1		-			0.56	0.23	1.35
			0.01 Favors	0.1 Provision	1 nal	10 Favors Two	100 Stents			
	2004 2004 2006 2008 2008	Provisional 2004 0 / 47 2004 0 / 22 2006 1 / 207 2008 2 / 101 2008 1 / 250 2009 2 / 173	Two Provisional Stents 2004 0 / 47 1 / 44 2004 0 / 22 3 / 63 2006 1 / 207 0 / 206 2008 2 / 101 2 / 101 2008 1 / 250 5 / 250 2009 2 / 173 3 / 177	Two Provisional stents 2004 0 / 47 1 / 44 2004 0 / 22 3 / 63 2006 1 / 207 0 / 206 2008 2 / 101 2 / 101 2008 1 / 250 5 / 250 2009 2 / 173 3 / 177 6 / 800 14 / 841 0.01 0.1 1 10 100	Two Provisional stents 2004					

Test for heterogeneity: Q=2.2, df=3, P=0.52 k=0% Test for overall effect: Z= -0.76, P=0.45

Fixed Effects Model

Randomized trial on routine vs. Provisional T-stenting in the treatment of de novo coronary bifurcation lesions (BBK)



More stent thrombosis with complex techniques?



Predictors of LST / VLST

Multivariable analysis

LST / VLST in 67 lesions among 16,801 lesions treated exclusively by Cypher


Factors	R.R.	95%C.I.	P √alue
Hemodialysis	1.91	(1.29 - 2.65)	0.002
ESRD (e-GFR < 30/Non-HD)	1.81	(1.2 - 2.65)	0.007
Two stents for bifurcation	1.81	(1.17 - 2.59)	0.01

Those variables with p value < 0.1 in the univariable analysis were incorporated into the multivariable model.

Provisional SB stenting




POT* technique




The POT technique should be used in any case of difficulty recrossing into a side branch with either a wire or balloon

Provisional SB stenting




Provisional SB stenting



NORDIC III

Primary end point event free survival

MACE (cardiac death, index lesion MI, TLR, stent thrombosis



Value of kissing inflations in simple stenting

Systematic kissing: no advantage / no harm


- When using a single stent technique, in the absence of kissing balloon inflations, the proximal main vessel stent should be postdilated to an appropriate diameter.

– Kissing balloon inflations, or pressure wire interrogation, should be used when an angiographically significant (>75%) side branch lesion remains after main vessel stenting.




SEA-SIDE: PROCEDURAL PREDICTORS OF POST-PCI INDUCIBLE ISCHEMIA






Significant Post Stenting SB Stenosis: QCA vs FFR

(jailed side branch lesions, n=94)



Provisional SB stenting




Non compliant high pressure balloons for kissing




Results

Cypher (J&J) SB Balloon



Dista1

Semi-Compliant Balloon (Ryujin Plus, Terumo)



Non-Compliant Balloon (Hiryu, Terumo)

Proximal

When to use two stents?

 Provisional T stenting remains the gold standard technique for most bifurcations.

Large side branches with ostial disease extending >5mm
 from the carina are likely to require a two-stent strategy.

 Side branches whose access is particularly challenging should be secured by stenting once accessed.

Which 2 stent technique?



Influence of Bifurcation Angle

Y-Shape



- ✓ Cush
- ✓ MiniCrush
- Culotte
- T Stenting


T-Shape



- T Stenting
- W Cush
- ✓ MiniCrush
- Culotte


Nordic II

Rate of main vessel and/or side branch in-stent diameter stenosis >50% at 8 months follow-up



Gunnes ACC 2008


Provisional Side Branch Stenting



Mandatory final kissing in complex techniques



Final Kissing Ballooning Is Important in 2-Stent Technique



- Ge L, JACC 2005
- Colombo A, CACTUS, Circulation 2009

Future of bifurcation stenting?

- Dedicated bifurcation stent systems remain limited but are likely ultimately to prevail (David Hildick-Smith)(BBC 1).

- "Bifurcation treatment without permanent implants = No discussions on bifurcation techniques" (Biodegradable stents)(Leif Thuesen)(NORDIC)

Conclusions

- Provisional SB stenting strategy is the gold standard: POT
- No advantage, no harm of systematic final KB: result, SB size,
 FFR ... non compliant balloons?
- When using 2 stents? With a mandatory kissing
 - long SB lesions (> 3 mm, > 5 mm?)
 - but why not provisional strategy?
 - very difficult SB access: SB first?
- When not to using SB stent first ?: Wide B angle
- Dedicated stents: randomized studies / biodegradable stents!

EuroIntervention

Consensus from the 5th European Bifurcation Club meeting

David Hildick-Smith^{1*}, MD; Jans Flensted Lassen², MD; Remo Albiero³, MD; Thierry Lefevre⁴, MD; Olivier Darremont⁵, MD; Manuel Pan⁶, MD; Miroslaw Ferenc⁷, MD; Goran Stankovic⁸, MD; Yves Louvard⁶, MD

1. Sussex Cardiac Centre, Brighton and Sussex University Hospitals, United Kingdom; 2. Department of Cardiology B, Skejby Hospital, University of Aarhus, Denmark; 3. Clinica San Rocco, Brescia, Italy; 4 Institut Cardiovasculaire Paris Sud, Massy, France; 5 Clinique Saint Augustin, Bordeaux, France; 6. Hospital Reina Sofia, Cordoba, Spain; 7. Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; 8. Institute for Cardiovascular Diseases, Clinical Center of Serbia, Belgrade, Serbia

The authors have no conflict of interest to declare.

EuroIntervention May 2010

WWW.bifurc.net